| Symbol | EDIT |
|---|---|
| Name | EDITAS MEDICINE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11 HURLEY STREET, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 401-9000 |
| Fax | — |
| — | |
| Website | https://www.editasmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001650664 |
| Description | Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The companys only operating segment is developing and commercializing genome editing technology. Additional info from NASDAQ: |
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
Read more📋 Burkly Linda (Officer) plans to sell 6K shares of Editas Medicine, Inc. (at $2.88 each, total $16K) Filed: Jul 21, 2026 | ID: 000074
Read moreDirector Connaughton Bernadette 🟢 acquired 51.7K shares (1 derivative) of Editas Medicine, Inc. (EDIT) at $2.55 Transaction Date: Jun 17, 2026 | Filing ID: 000072
Read moreDirector Hopfield Jessica 🟢 acquired 51.7K shares (1 derivative) of Editas Medicine, Inc. (EDIT) at $2.55 Transaction Date: Jun 17, 2026 | Filing ID: 000071
Read moreDirector Scadden David 🟢 acquired 51.7K shares (1 derivative) of Editas Medicine, Inc. (EDIT) at $2.55 Transaction Date: Jun 17, 2026 | Filing ID: 000069
Read moreDirector Levy Elliott M. 🟢 acquired 51.7K shares (1 derivative) of Editas Medicine, Inc. (EDIT) at $2.55 Transaction Date: Jun 17, 2026 | Filing ID: 000068
Read moreParison Amy 🔴 sold 464 shares of Editas Medicine, Inc. (EDIT) at $2.70 Transaction Date: Jun 03, 2026 | Filing ID: 000057
Read moreDirector O'Neill Gilmore Neil 🔴 sold 15.4K shares of Editas Medicine, Inc. (EDIT) at $2.70 Transaction Date: Jun 03, 2026 | Filing ID: 000056
Read moreBurkly Linda 🔴 sold 731 shares of Editas Medicine, Inc. (EDIT) at $2.70 Transaction Date: Jun 03, 2026 | Filing ID: 000055
Read moreNew Form SCHEDULE 13G - Editas Medicine, Inc. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001346824-26-000168 <b>Size:</b> 18 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06363760 | A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfu… | — | Sickle Cell Disease | Enrolling_By_Invitation | 2024-06-17 | 2040-08-01 | ClinicalTrials.gov |
| NCT05444894 | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participan… | Phase1 | Transfusion Dependent Beta Thalassemia | Active_Not_Recruiting | 2022-04-29 | 2025-12-01 | ClinicalTrials.gov |
| NCT04853576 | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Sev… | Phase1 | Sickle Cell Disease | Active_Not_Recruiting | 2021-05-04 | 2025-08-01 | ClinicalTrials.gov |
| NCT03872479 | Single Ascending Dose Study in Participants With LCA10 | Phase1 | Leber Congenital Amaurosis 10 | Unknown | 2019-09-26 | 2025-05-23 | ClinicalTrials.gov |
| NCT03396042 | Natural History Study of CEP290-Related Retinal Degeneration | — | Blindness | Completed | 2017-12-17 | 2022-05-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EDIT-301 | Other | Phase PHASE1 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04853576 |
| EDIT-101 | Other | Phase PHASE1 | Leber Congenital Amaurosis 10 | UNKNOWN | NCT03872479 |
| Safety and efficacy assessments | Other | Preclinical | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT06363760 |
| EDIT-301 | Other | Phase PHASE1 | Transfusion Dependent Beta Thalassemia | ACTIVE_NOT_RECRUITING | NCT05444894 |
| Safety and efficacy assessments | OTHER | Preclinical | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT06363760 |
| EDIT-301 | GENETIC | Phase PHASE1 | Transfusion Dependent Beta Thalassemia | ACTIVE_NOT_RECRUITING | NCT05444894 |
| EDIT-101 | DRUG | Phase PHASE1 | Leber Congenital Amaurosis 10 | UNKNOWN | NCT03872479 |